Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jianmin Pharmaceutical Group Co., Ltd. is a leading player in China's pharmaceutical sector, specializing in the production of generic and specialty drugs. The company benefits from a robust distribution network across various provinces in China and a diverse product portfolio that includes cardiovascular and anti-infective medications.
Jianmin generates revenue primarily through the sale of generic pharmaceuticals, leveraging its cost advantages due to low production costs and strong relationships with healthcare providers. The company has pricing power in the generic segment due to its established brand reputation and extensive distribution channels.
Regulatory approvals for new drugs
Changes in government healthcare policies affecting drug pricing
Market share shifts in the generic drug segment
Fluctuations in raw material costs impacting margins
Regulatory changes that could impact drug pricing and reimbursement
Technological advancements in drug development that could outpace current offerings
Intensifying competition from both domestic and international generic manufacturers
Potential for price erosion in the generic drug market
Low liquidity risk due to a current ratio of 1.55
Potential risks associated with R&D investments not yielding expected results
moderate - As a pharmaceutical manufacturer, Jianmin's performance is somewhat insulated from economic cycles, but demand for non-essential medications may decline in downturns.
Low - Jianmin's low debt levels (Debt/Equity of 0.09) minimize sensitivity to interest rate changes, although higher rates could impact consumer spending on healthcare.
minimal - The company operates with low leverage, reducing its exposure to credit market fluctuations.
value - Investors may be attracted to Jianmin due to its low valuation metrics and stable cash flows despite recent revenue declines.
moderate - The stock has shown significant price fluctuations, with a 1-year return of -35.0%, indicating potential volatility.